Ceapro Inc V.CZO

Chemicals Specialty Chemicals

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

TSXV:CZO - Post by User

Ceapro Inc > 7%

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Sep 26, 2023 10:49am

33 Views

Post# 35654464

RE:7%

"Jamie Dimon is still telling clients to prepare for a worst-case scenario of benchmark interest rates hitting 7% along with stagflation. .... Dimon, who has said rates may need to rise further to fight inflation, added that the difference between 5% and 7% would be more painful for the economy than going from 3% to 5% was." Bloomberg

prophetoffactz wrote: The S&P Biotech is now down about 12% this year alone with only about nine months complete. It's down ~59% of from its high of less than three years ago during the most brutal biotech bear market in history. As I've said, this is a time for survival in biotech and to prove resilience. The windfall gains will typically have to wait until interest rates start sustainably falling once again. boazklinghorn's darling ABCL is now down about 52% since the beginning of the year. ABCL is down a staggering ~92% in less than three years. Assets that don't make money and burn lots of cash with payouts long in the future are being hit hard. If the risk-free FED rate climbs to 7%, as JP Morgan's CEO believes may be in store, imagine what internal rate of return is needed for a microcap biotech given it isn't a risk-free asset. Its a very tough hurdle for many biotech companies to jump. High interest rates are a different world for biotech and many biotech companies are going into bankruptcy or reorganization as they struggle. CZO is positioned to pick over the rubble of a biotech landscape in crisis and see if it can combine assets to build a viable company that needs growing levels of cash to become a biopharma in the future. When interest rates start to fall again then it will be a new bull market. If the world is potentially headed to a risk-free FED rate of 7%, that it is currently unprepared for, there could be more sharp loses in biotech ahead. A 7% FED rate is a stunning 31% higher than the current FED rate of 5.33%. The Canadian economy could be crushed which could significantly help an exporter to the US like CZO as long as the US consumer holds up in CZO's product category. Let's hope CZO's plans include fortress cash balances, material near-term revenue generation, flexability to adjust in a continued biotech cash crunch, and that PGX progresses cleanly in this scale-up with a short time to potential pay-off. With high interest rates it needs to be a very compelling project to justify the risk. This is a market for caution until the dust settles. Some believe the world is headed to a nasty credit event as a decade of ~0% interest rates meets the sudden and unexpected shock of a 5-7% risk-free FED funds rate and the global economy copes with its debt.